| Life Strategies Counseling Services Inc. | |
|
120 Harper Ct Beckley WV 25801-2650 | |
| (304) 255-7526 | |
| Not Available |
| Full Name | Life Strategies Counseling Services Inc. |
|---|---|
| Speciality | Social Worker |
| Location | 120 Harper Ct, Beckley, West Virginia |
| Authorized Official Name and Position | Hamlet Don Smith (PRESIDENT) |
| Authorized Official Contact | 3042557526 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Life Strategies Counseling Services Inc. Po Box 5084 Beckley WV 25801-7500 Ph: (304) 255-7526 | Life Strategies Counseling Services Inc. 120 Harper Ct Beckley WV 25801-2650 Ph: (304) 255-7526 |
| NPI Number | 1700837143 |
|---|---|
| Provider Enumeration Date | 05/12/2006 |
| Last Update Date | 08/22/2020 |
| Medicare PECOS PAC ID | 6002819687 |
|---|---|
| Medicare Enrollment ID | O20060821000561 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700837143 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | DP00939981 (West Virginia) | Primary |
| Provider Name | Kerri Elizabeth White |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1427113299 PECOS PAC ID: 1557547668 Enrollment ID: I20110525000172 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Provider Name | Nancy R Carlson |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1124361407 PECOS PAC ID: 6103138482 Enrollment ID: I20150629002028 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Provider Name | Joy L Napier |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1770790933 PECOS PAC ID: 8123330412 Enrollment ID: I20180308000983 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Provider Name | Bethany L Gravely |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1245732262 PECOS PAC ID: 1951656610 Enrollment ID: I20180620002316 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Provider Name | Beverly Lynn Lafferty |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1588115836 PECOS PAC ID: 5395093066 Enrollment ID: I20180813002112 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Provider Name | Jason Don Moore |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1801247879 PECOS PAC ID: 9133486400 Enrollment ID: I20200626001540 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Provider Name | Kimberly J Harrison |
|---|---|
| Provider Type | Practitioner - Clinical Social Worker |
| Provider Identifiers | NPI Number: 1609500271 PECOS PAC ID: 4183009103 Enrollment ID: I20220912002484 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
| Provider Name | Yosely K Cruz-fernandez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942573522 PECOS PAC ID: 5890929145 Enrollment ID: I20221017001741 |
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
News Archive
Osteopontin (OPN), a protein molecule involved in many different cellular processes, plays a significant role in immune deficiency and organ atrophy following chronic physiological stress, resulting in increased susceptibility to illness.
Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.
This is a set of malignancies that arise in germ cells of the testicles, the specialized cells that produce sperm. Taken together, testicular cancers are the most common form of malignancy that occurs in young men (approximately 15 to 35 years of age).
Scientists at the Wyss Institute for Biologically Inspired Engineering at Harvard University developing novel nanotherapeutics for clearing obstructed blood vessels have teamed up with researchers at University of Massachusetts' New England Center for Stroke Research (NECSTR) to develop a new, highly effective drug-device combination for treating life-threatening blood clots in patients with stroke.
PLAQUETEC LTD today announced the publication of the first peer‐reviewed article demonstrating the feasibility and potential of the PlaqueTec Liquid Biopsy System™ to detect biomarkers for coronary artery disease (CAD).
› Verified 8 days ago
Amaris Medical, Llc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1810 Harper Rd, Beckley, WV 25801 Phone: 681-207-7007 Fax: 681-207-7073 | |
Endless Possibilities Counseling Services Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 300 N Kanawha St, Beckley, WV 25801 Phone: 304-923-2862 | |
Elena Behavioral Health Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 379 Stanaford Rd Ste 200, Beckley, WV 25801 Phone: 304-253-3000 Fax: 304-929-2038 | |
Fmrs Health Systems Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 101 S Eisenhower Dr, Beckley, WV 25801 Phone: 304-256-7100 Fax: 304-256-7160 | |
Nuskool Scholars Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 109 E Main St, Beckley, WV 25801 Phone: 304-250-4210 Fax: 681-207-1037 | |
Appalachian Psychiatric Services Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1014 Johnstown Rd, Beckley, WV 25802 Phone: 304-252-4433 Fax: 304-252-1703 | |
Misti Jones Wheeler Ms Inc. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 805 Johnstown Rd, Beckley, WV 25801 Phone: 304-929-3945 Fax: 304-929-3945 |